Observational studyBlood2014
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Observational study in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 2 syntheses or guidelines pooled it, 197 citations in OpenAlex.
- Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review.Clinical lymphoma, myeloma & leukemia · 2025Pooled it
- Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis.European radiology · 2017Pooled it
- Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- The transcriptomic profile of CD138Haematologica · 2019Trial
- Trial
- Review
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.Clinical lymphoma, myeloma & leukemia · 2025Article
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma.Cancer biomarkers : section A of Disease markers · 2025Article
- Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma.Research square · 2025Article
- Smoldering multiple myeloma: Integrating biology and risk into management.Seminars in hematology · 2025Review
- Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions.Diagnostics (Basel, Switzerland) · 2025Review
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.Blood cancer journal · 2024Article
- Detection of myeloma-associated osteolytic bone lesions with energy-integrating and photon-counting detector CT.Radiologie (Heidelberg, Germany) · 2024Article
- Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens.Journal of translational medicine · 2024Article
- Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.Hematology/oncology clinics of North America · 2024Review
- pyComBat, a Python tool for batch effects correction in high-throughput molecular data using empirical Bayes methods.BMC bioinformatics · 2023Article
- A gene signature can predict risk of MGUS progressing to multiple myeloma.Journal of hematology & oncology · 2023Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
All cases of clinical myeloma (CMM) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monoclonal gammopathy of undetermined significance (MGUS) or asymptomatic multiple myeloma (AMM). We analyzed data from AMG patients (n = 331) enrolled in a prospective, observational clinical trial (S0120). Baseline data from clinical variables, gene expression profiles (GEP) of purified tumor cells, and findings of magnetic resonance imaging (MRI) were correlated with the risk of progression to CMM requiring therapy. GEP of purified tumor cells revealed that all molecular subtypes of CMM are also represented in the AMG phase. An increased risk score (>-0.26) (based on a 70-gene signature, GEP70) was an independent predictor of the risk of progression to CMM. Combination of elevated serum free light chain, M-spike, and GEP70 risk score identified a subset with high risk (67% at 2 years) of progression to CMM requiring therapy. Importantly, absence of these factors in AMM patients predicted low risk similar to MGUS. Detection of multiple (>1) focal lesions by MRI also conferred an increased risk of progression. These data demonstrate that signatures associated with high-risk CMM impact disease risk and support inclusion of genomic analysis in the clinical management of AMGs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.